Related Experiment Video
Updated: Jul 9, 2026

07:13
The Unpredictable Chronic Mild Stress Protocol for Inducing Anhedonia in Mice
Published on: October 24, 2018
CSF galanin and noradrenaline downregulation by psilocybin therapy in major depressive disorder
Wojciech Paslawski1, Daniel Doyon1, Carl Johan Ekman2
1Translational Neuropharmacology, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
Abstract:
Psilocybin is a rapid-acting antidepressant, but its mechanism of action in major depressive disorder remains unclear. In this secondary analysis of randomized, placebo-controlled trial with multimodal CSF and blood biomarker measurements, psilocybin selectively reduced CSF galanin and noradrenaline, implicating that normalization of these co-transmitters is a key pharmacodynamic signature.

